4//SEC Filing
Jacobs Bruce N. 4
Accession 0001193125-25-206350
CIK 0001815442other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 5:16 PM ET
Size
11.0 KB
Accession
0001193125-25-206350
Insider Transaction Report
Form 4
Jacobs Bruce N.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-09-17$50.00/sh−79,220$3,961,380→ 227,409 total - Exercise/Conversion
Common Stock
2025-09-17$2.08/sh+79,220$164,778→ 306,629 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-17−42,246→ 27,653 totalExercise: $2.08Exp: 2029-08-28→ Common Stock (42,246 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-17−36,974→ 0 totalExercise: $2.08Exp: 2029-08-28→ Common Stock (36,974 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
- [F2]This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.90 to $50.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821074
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 5:16 PM ET
- Size
- 11.0 KB